Succinate dehydrogenase (SDH) is a heterotetrameric nuclear-encoded complex responsible for the oxidation of succinate to fumarate in the tricarboxylic acid cycle. Loss-of-function mutations in any of the SDH genes are associated with cancer formation. However, the impact of SDH loss on cell metabolism and the mechanisms enabling growth of SDH-defective cells are largely unknown. Here, we generated Sdhb-ablated kidney mouse cells and used comparative metabolomics and stable-isotope-labelling approaches to identify nutritional requirements and metabolic adaptations to SDH loss. We found that lack of SDH activity commits cells to consume extracellular pyruvate, which sustains Warburg-like bioenergetic features. We further demonstrated that pyruvate carboxylation diverts glucose-derived carbons into aspartate biosynthesis, thus sustaining cell growth. By identifying pyruvate carboxylase as essential for the proliferation and tumorigenic capacity of SDH-deficient cells, this study revealed a metabolic vulnerability for potential future treatment of SDH-associated malignancies.
The tricarboxylic acid (TCA) cycle is a pivotal source for mitochondrial NADH and the core metabolic route for production of many biosynthetic precursors. Over the past 15 years, oncogenic mutations in three TCA-cycle-related enzymes, SDH, fumarate hydratase (FH) and isocitrate dehydrogenase have been identified 1 . Although these discoveries may implicate altered metabolism as an underlying hallmark of neoplastic transformation, they left the question of how these cancer cells fulfil bioenergetic and anabolic demands largely unresolved.
SDH is a heterotetrameric nuclear-encoded protein complex responsible for oxidation of succinate to fumarate in the TCA cycle and for feeding electrons into the mitochondrial respiratory chain for ATP production (complex II). Inactivating mutations in the human genes for any of the SDH subunits, or the SDH complex assembly factor (SDHAF2), are associated with susceptibility to develop neuroendrocrine neoplasms and gastrointestinal stromal tumours as well as renal cell carcinoma (RCC; refs 2-13) . Loss of SDH causes succinate accumulation in cells, which activates hypoxia-inducible factors at normal oxygen tension and inhibits α-ketoglutarate-dependent histone and DNA demethylases, thereby establishing, respectively, a pseudohypoxic and hypermethylator phenotype in tumours [14] [15] [16] .
Although SDH is the first discovered TCA cycle enzyme with tumour suppressor properties, the metabolic consequences of disabling SDH and the molecular mechanisms enabling survival and growth of SDH-defective cells remain largely unexplored. Knowledge of the metabolic profile of SDH-mutated tumours is limited and largely inferred from a few steady-state metabolic changes observed in situ in human studies. However, whereas pan-metabolomic analyses are useful to identify biochemical signatures for tumour stratification, they do not allow for the understanding of biochemical fluxes necessary to disclose targetable cancer metabolic vulnerabilities. Considering this limitation, the RNA interference-mediated silencing of SDH subunits in cancer cells enabled a partial understanding of cellular effects of mitochondrial complex II deficiency 14, 15, 17 . However, as SDH levels are never completely depleted by RNAi, the residual SDH activity might still play a role in succinate oxidation in mitochondria, thereby masking the effective rewiring of metabolic networks in tumours devoid of functional SDH. To overcome this limitation, we generated Sdhb-ablated immortalized kidney mouse cells, and by unsupervised metabolomic screenings and isotopelabelling approaches we identified metabolic pathways essential to support their proliferation. We found that SDHB loss is sufficient Supplementary Table 3. to ensure a complete block of the TCA cycle and to drive Warburglike bioenergetic features of aerobic glycolysis in proliferating cells. We demonstrated that ablation of SDH activity commits cells to consume extracellular pyruvate needed to sustain maximal glycolytic flux and support the diversion of glucose-derived carbons into aspartate biosynthesis through pyruvate carboxylase (PCX for mouse and PC for human). By identifying Pcx as essential for SDH-deficient but dispensable for normal cells, this study unveils a metabolic vulnerability for potential treatment of SDH-associated neoplasms.
RESULTS

Sdhb deletion induces complete truncation of the TCA cycle and commits cells to fulfil energetic needs through glycolysis
To predict and validate metabolic alterations induced by FH loss, we previously used genetically modified kidney mouse cells from which Fh1 had been deleted [18] [19] [20] . Similarly, to disclose metabolic rewiring induced by SDH loss, we first produced genetically modified mice containing loxP sites flanking exon 3 of the endogenous Sdhb gene ( Supplementary Fig. 1a ), and then immortalized primary kidney epithelial cells isolated from these mice (Sdhb fl/fl ). To generate Sdhb knockout cells (Sdhb ∆/∆ ), Sdhb fl/fl cells were infected with recombinant adenovirus expressing Cre recombinase. Two clones (Sdhb ∆/∆ -CL 5 and Sdhb ∆/∆ -CL 7) were selected from the infected pool and genetically confirmed to contain homozygous Sdhb-deleted alleles ( Supplementary Fig. 1b ,c). Suppression of exon 3 leads to a premature stop codon, and as a result Sdhb ∆/∆ cells presented with a complete loss of SDHB protein production and complete impairment of the overall SDH complex activity ( Supplementary Fig. 1d ,e). Carbon supply to the TCA cycle is achieved mainly through the catabolism of glucose and glutamine. Therefore, to reveal the effects of SDHB loss on TCA cycle function, cells were cultured in medium containing uniformly labelled (U)-13 C-glucose or U-13 C-glutamine, and the 13 C labelling of succinate and fumarate was analysed by liquid chromatography-mass spectrometry (LC-MS). SDHB loss gave rise to a build-up of intracellular succinate, which reached levels approximately 200 times higher than those of Sdhb fl/fl cells, and a concomitant decrease of fumarate ( Fig. 1a-d ). When U-13 C-glucose was used, less than 15% of cellular succinate was labelled ( Fig. 1a ). However, over 80% of the succinate was fully labelled ( 13 C 4 ) when cells were cultured with U-13 C-glutamine ( Fig. 1b ), indicating that glutamine is a major source of carbons for the TCA cycle in both Sdhb fl/fl and Sdhb ∆/∆ cells. Importantly, the fumarate pool of the Sdhb fl/fl cells fed with either 13 C 6 -labelled glucose or 13 C 5 -labelled glutamine contained considerable fractions of isotopologues with two and four 13 C atoms respectively, owing to the processing of succinate in and beyond the SDH step ( Fig. 1c,d ). The absence Supplementary Table 3 .
of these isotopologues from Sdhb ∆/∆ cells demonstrates that loss of SDHB is sufficient to block the TCA cycle ( Fig. 1c,d ). FADH 2 , generated during SDH catalysis, and NADH, produced mainly in the mitochondria by other dehydrogenases, feed the respiratory chain for oxygen consumption and ATP production. Therefore, the effects of complex II deficiency and TCA cycle truncation on the oxygen consumption rate (OCR) of SDH-null cells were investigated. Sdhbdeficient clones show lower basal mitochondrial respiration with respect to SDH-proficient cells (Fig. 1e ). This feature was strongly associated with a reduced entry of glucose carbons into the TCA cycle through pyruvate dehydrogenase, as indicated by the diminished pool of citrate containing two 13 C atoms in SDHB-null cells fed with U-13 C-glucose with respect to normal counterparts ( Fig. 1f ). In line with this finding, lower labelling of lipogenic acetyl-CoA (AcCoA) from glucose was observed in SDH-null cells when compared with their normal counterparts ( Supplementary Fig. 1f ). In contrast, glutamine represents the main source of labelled lipogenic AcCoA when SDHB is lost ( Supplementary Fig. 1f ). In-depth analysis of the respiratory profile indicated that, whereas under basal conditions Sdhb fl/fl cells consume molecular oxygen at a submaximal capacity, both the maximal OCR and the reserve capacity are reduced on SDH loss, indicating that Sdhb ∆/∆ cells respire at a rate close to their bioenergetic limit ( Fig. 1e and Supplementary Fig. 2a ). Importantly, the near complete loss of oxygen consumption is not due to a reduction in the number of mitochondria. Indeed, as observed in SDHB-associated renal cell tumours 21 , SDH-null cells show an increase in mitochondrial mass ( Supplementary Fig. 2b ). Importantly, the OCR decline was also associated with the specific decrease of mitochondrial complex I proteins, as previously reported for SDH-defective neuroendocrine tumours 22 , and with the resulting drop of its catalytic activity ( Supplementary Fig. 2c,d ). It is worth noting that approximately 60% of the mitochondrial respiration is coupled to oxidative phosphorylation in Supplementary Table 3 . Table 2 ). The cell proliferation marker Ki-67 identifies hyperproliferative neoplastic areas of the section. NAT, normal adjacent tissue; T, tumour. Scale bars, 100 µM. Raw data of independently repeated experiments are provided in Supplementary Table 3 . Fig. 2a ). This indicates that oxidative phosphorylation contributes only marginally to ATP synthesis when SDH activity is lost. In line with these respiratory adjustments, the ATP-synthase inhibitor oligomycin induced energetic stress in Sdhb fl/fl cells only, preferentially limiting their proliferation ( Fig. 1g and Supplementary Fig. 2e ,f). The respiratory features of SDH-null cells imply that their ATP requirements must be fulfilled mainly by glycolysis. In line with this deduction, the reduced OCR of Sdhb ∆/∆ cells is associated with an increase in the glycolytic flux, as indicated by the augmented extracellular acidification rate ( Supplementary Fig. 2g ) and confirmed by the increase in glucose consumption and lactate production rates ( Fig. 1h ). Importantly, whereas glycolysis inhibition elicited by the 800 Supplementary Table 3 .
lactate dehydrogenase inhibitor oxamate did not affect the energetic status of Sdhb fl/fl cells, it raised the AMP/ATP ratio in SDH-null cells and selectively impaired their proliferative potential ( Fig. 1g and Supplementary Fig. 2h-j) .
Extracellular pyruvate is required to maintain maximal glycolytic flux and to enable proliferation of Sdhb-null cells
To study the changes in cell metabolism on SDHB loss, the exchange rate of metabolites between cells and the extracellular medium was profiled by LC-MS. In accordance with being the main carbon source for the TCA cycle, glutamine was the second most consumed metabolite by all cell types, but with different rates ( Supplementary  Fig. 3a) . Interestingly, despite the presence of pyruvate in the medium, a net secretion of this organic acid by Sdhb fl/fl cells was observed. In contrast, pyruvate ranks as the third most consumed metabolite in the SDH-null clones ( Supplementary Fig. 3a ). In agreement with this metabolic feature, pyruvate deprivation selectively impaired the proliferation of Sdhb ∆/∆ cells, sparing their normal counterparts ( Fig. 2a ). Whereas Sdhb ∆/∆ cells consumed pyruvate, this exogenous metabolite contributed only marginally to its intracellular pool, as found by incubating cells in U-13 C-pyruvate ( Supplementary Fig. 3b ). Moreover, as it is mainly synthesized de novo through glycolysis, the Supplementary Table 3 .
large majority of intracellular pyruvate was fully labelled ( 13 C 3 ) in cells cultured with U-13 C-glucose ( Supplementary Fig. 3c) . Surprisingly, when pyruvate was deprived from the medium, intracellular steadystate levels of this metabolite were markedly decreased in Sdhb ∆/∆ clones, suggesting that the demand for pyruvate exceeded the cells' biosynthetic capacity ( Supplementary Fig. 3c ). By converting pyruvate to lactate, lactate dehydrogenase restores the NAD + pool, which is rate limiting for glycolytic flux. Similarly, an extra pool of NAD + , derived from the synthesis of lactate from extracellular pyruvate, may enable SDH-null cells to maximize their glycolytic capacity and divert some glucose-derived carbons for biomass generation (Fig. 2b) . In agreement with this hypothesis, the conversion rate of exogenous pyruvate into lactate ( 13 C 3 -lactate) was almost 2.5 times higher in Sdhb ∆/∆ than in Sdhb fl/fl cells (Fig. 2c) , and the NAD + /NADH ratio was decreased in pyruvate-deprived Sdhb ∆/∆ cells, as well as in lactate dehydrogenase-inhibited cells ( Fig. 2d and Supplementary Fig. 2k-m) .
As a result of the NAD + /NADH imbalance, a marked accumulation of pentose phosphate pathway and glycolytic intermediates upstream of the NAD + -dependent oxidation of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate was observed in pyruvate-deprived SDHdeficient cells (Fig. 2e ). In line with these observations, a consequent decrease in glucose-derived lactate ( 13 C 3 -lactate) secretion and glucose ( 13 C 6 -glucose) consumption rates were measured on pyruvate depletion (Fig. 2f ), demonstrating that SDHB loss constrains cells to the uptake of extracellular pyruvate to sustain maximal glycolytic flux.
Glucose-dependent aspartate biosynthesis dictates pyruvate dependence of Sdhb-deficient cells
To obtain further insights into metabolic changes due to SDH loss, an untargeted endo-metabolomic profiling coupled with multivariate statistics was carried out (Supplementary Table 1 ). The principal component analysis showed a clear separation between SDH-null and SDH-containing cells. Moreover, the occurrence of sub-clustering of pyruvate-fed and pyruvate-deprived Sdhb ∆/∆ cells, but not Sdhb fl/fl cells, indicates that the removal of pyruvate from the medium generates a metabolic signature only when Sdhb is deleted (Fig. 3a) .
Metabolite profiling (in the presence of pyruvate) revealed that, as expected, succinate is the most increased metabolite in the SDH-deficient cells as compared with control cells. Interestingly, however, formiminoglutamic acid (FIGLU), a catabolic product of histidine, and aspartate, a non-essential amino acid synthesized de novo from oxaloacetate, ranked as the first and second most decreased metabolites in SDH-null cells (Fig. 3b ). Furthermore, in agreement with this in vitro observation, these metabolic changes were also detected in human SDH-mutated paragangliomas and pheochromocytomas with respect to SDH-unrelated tumours ( Fig. 3c and Supplementary Tables 2 and 3) , thus validating our in vitro observations. Furthermore, the steady-state levels of aspartate, but not FIGLU, were further dampened about fourfold on pyruvate withdrawal in Sdhb ∆/∆ cells, whereas they remained unchanged in SDHB-proficient cells ( Fig. 3d and Supplementary Table 1 ). Supporting these observations, de novo biosynthesis of aspartate ( 15 N-aspartate) was decreased in Sdhb ∆/∆ cells cultured with α-15 N-glutamine and was further diminished on pyruvate deprivation ( Fig. 3e ), suggesting that reduced aspartate availability for biomass generation may underlie the pyruvate dependence of SDH-deficient cells. In line with this hypothesis, supraphysiological aspartate supplementation elevated its intracellular steady-state levels ( Fig. 3f ) and almost completely relieved the pyruvate addiction of Sdhb ∆/∆ cells (Fig. 3g ). To further explore the influence of exogenous pyruvate availability on aspartate biosynthesis, we analysed the pattern of fractional 13 C enrichment of this amino acid after culturing cells in the presence of U-13 C-pyruvate, U-13 C-glutamine or U-13 Cglucose (Fig. 3h) . The 13 C-enrichment profiles revealed that less than 10% of the total aspartate pool contained isotopologues derived from extracellular pyruvate, regardless of cell genotype. Rather, approximately 80% of aspartate was derived from glutamine in Sdhb fl/fl cells, whereas, owing to TCA cycle truncation, glutamine carbons contributed to less than 20% of aspartate production through reductive carboxylation ( 13 C 3 ) in Sdhb ∆/∆ cells. Surprisingly, whereas glucose supplied only 20% or less of the aspartate pool in Sdhb fl/fl cells, approximately 45% of aspartate carbons were derived from glucose in SDH-null cells. Therefore, as pyruvate accelerates the glycolytic flux in Sdhb ∆/∆ cells, we postulated that it would also sustain the diversion of glucose-derived carbons into the aspartate biosynthetic pathway. Accordingly, the relative contribution of glucose carbons to the aspartate pool dropped from 45% to 15% in Sdhb ∆/∆ cells on pyruvate withdrawal, whereas it remained unaffected in SDHproficient counterparts (Fig. 3i ).
Pyruvate carboxylase expression is induced in SDH-deficient cells and SDHx-mutated human tumours
In Sdhb fl/fl cells, glucose mainly provides two carbons ( 13 C 2aspartate) to the aspartate skeleton by pyruvate oxidation in the TCA cycle through pyruvate dehydrogenase. In contrast, the U-13 Cglucose-derived aspartate pool of Sdhb ∆/∆ cells contained exclusively isotopologues with three 13 C atoms. This indicated that loss of SDH primed cells to engage pyruvate carboxylase to generate oxaloacetate (Figs 3i and 4a) . This was further supported by the observation that, in Sdhb ∆/∆ cells cultured with U-13 C-glucose, the fractional 13 Cenrichment of malate and fumarate recapitulated that of aspartate (Figs 1c and 4a,b) . Potential increased PC activity (on the basis of the labelling pattern of glucose-derived TCA cycle metabolites) was recently also observed in patient-derived FH-deficient RCC (refs 23,24) . Furthermore, it was previously suggested that PC may become essential for SDH-and FH-deficient cells 25 . PCX fixates bicarbonate into pyruvate to generate oxaloacetate. Therefore, as a further test of PCX activity, cells were cultured in the presence of 13 Cbicarbonate, and the kinetics of synthesis of 13 C 1 -aspartate and 13 C 1malate were monitored. In agreement with our related findings, both 13 C-labelled metabolites were enriched faster in SDH-null cells when compared with normal counterparts (Fig. 4c,d) . Furthermore, the PCX protein level was upregulated in Sdhb ∆/∆ cells (Fig. 4e ) in association with an enhancement in its gene expression ( Fig. 4f ), substantiating the increase in enzyme activity. To extend the impact of these findings and to gain insights into whether pyruvate carboxylase is related to SDH-deficient cancer pathophysiology, we analysed PC expression in SDH-defective human tumours. PC was found to be induced in SDHxmutated paragangliomas and pheochromocytomas with respect to non-SDHx-mutated tumours (Fig. 4g ). In addition, stronger granular cytoplasmic immunostaining of PC was revealed in tumour epithelial cells of human SDHB-mutated RCC when compared with their normal adjacent renal tissues ( Fig. 4h and Supplementary Fig. 4a ).
Pyruvate carboxylase sustains proliferation and tumorigenic capacity of transformed Sdhb-null cells
Our findings prompted us to investigate the essentiality of PCX for growth of SDH-deficient cells. With this aim, Pcx expression was stably silenced by three independent short hairpin RNAs (shRNAs) through lentiviral infection ( Supplementary Fig. 4b ). This reduced the incorporation of 13 C carbons derived from U-13 C-glucose ( Fig. 5a and Supplementary Fig. 4c ) or from 13 C-bicarbonate ( Fig. 5b and Supplementary Fig. 4d ) into both malate and aspartate, without eliciting appreciable changes in the contribution of glutamine carbons to the pool of this amino acid ( Supplementary Fig. 4e ). Furthermore, silencing of Pcx significantly reduced the proliferation of SDHnull cells in vitro, sparing the normal counterparts ( Fig. 5c ). We then evaluated the role of PCX in vivo by xenografting H-RAS V12transformed Sdhb fl/fl and Sdhb ∆/∆ cells in immunodeficient mice after silencing Pcx expression using two different shRNAs ( Fig. 5d and Supplementary Fig. 4f ). PCX downregulation in SDH-proficient cells did not result in a significant alteration in tumour initiation and growth (Fig. 5e-g and Supplementary Fig. 4g-i) . In contrast, PCX was required to support tumorigenesis in SDHB-deficient cells. Indeed, mice xenografted with Sdhb ∆/∆ -Pcx shRNA cells gave rise to tumours with a significantly delayed onset in both experiments. It is worth noting that, whereas tumour formation was observed only in two out of nine mice xenografted with Sdhb ∆/∆ -Pcx-1 shRNA cells, tumours emerged in all mice injected with Sdhb ∆/∆ -Pcx-5 shRNA cells, but exhibited a significantly reduced growth with respect to their PCXexpressing counterparts (Fig. 5e-g and Supplementary Fig. 4g-i) .
Pyruvate carboxylase enables growth of Sdhb-null cells by supporting aspartate biosynthesis
PC is required for the growth of cancer cells under in vitro glutaminedeprived conditions and enables cells to use glucose-derived pyruvate, rather than glutamine, for replenishing TCA cycle intermediates that are used in cataplerotic reactions, such as fatty acids (palmitate) biosynthesis 26 . However, our results suggest that the engagement of PCX provides SDH-deficient cells with a metabolic adaptation that mainly supports aspartate production. Indeed, compared with aspartate, PCX contributes marginally to citrate labelling ( 13 C 3 -citrate and 13 C 5 -citrate) ( Supplementary Fig. 5a ). Moreover, citrate and palmitate steady-state levels remained unchanged in Pcx-silenced cells (Fig. 6a,b) , and, whereas their proliferative capacity was completely rescued by aspartate supplementation, providing excess palmitate to Pcx-silenced SDH-deficient cells did not support in vitro proliferation (Fig. 6c,d and Supplementary Fig. 5b,c) . The rescue of the growth of Pcx-silenced SDH-deficient cells by aspartate also indicates that the effect of both shRNAs used to silence Pcx is on target.
DISCUSSION
Cancer cell metabolism is shaped by changing fluxes along key metabolic pathways and altering nutrient utilization to support biomass accumulation required for continuous mitotic divisions. Here, we show that the impairment of mitochondrial bioenergetics due to SDHB deficiency results in dependence on extracellular pyruvate to sustain the glycolytic flux and to direct glucose-derived carbons into aspartate biosynthesis through pyruvate carboxylase. Whereas the anaplerotic oxidative metabolism of glutamine into the TCA cycle enables SDH-proficient cells to replenish TCA cycle intermediates, which are required for the production of cellular building blocks, the TCA cycle truncation forces SDH-null cells to rely on PCX to generate oxaloacetate. The impact of these findings is strengthened by the histopathological observation that high-proliferation regions of SDHB-mutated RCC are characterized by higher PC expression in comparison to low-proliferation areas in the same tumour and in normal adjacent tubules (Fig. 4h ). However, although our results suggest a direct link between PC levels and SDHB loss in renal cancers and neuroendocrine tumours, induction of PC gene expression may be dispensable, as metabolic fluxes through this enzyme can be shaped by allosteric regulation of PC function 27 and by post-transcriptional modulation of PC protein abundance 26 . In fact, the extent of the induction of Pcx RNA in SDH-deficient cells was inconsistent (compare Fig. 4f to Supplementary Fig. 4b) ; nevertheless, the induction of PCX activity in these cells, as measured by bicarbonate-derived 13 C incorporation into aspartate, was equivalently high (compare Fig. 4c to Fig. 5b ). It is noteworthy that PC was recently found to be essential for nonsmall-cell lung cancer proliferation 28 . Furthermore, FH deficiency 23, 24 or the expression of oncogenic IDH1 mutation 29 , increased anaplerotic contribution of pyruvate carboxylation, although no essentiality of PC in these cells was reported.
Beyond the direct contribution to protein biosynthesis, aspartate is the precursor for asparagine as well as pyrimidine and purine nucleotides, and as aspartate is not abundant in human plasma its de novo synthesis is required for cell growth and proliferation. Therefore, by relating the glycolytic dependence of SDH-null cells to aspartate biosynthesis through PC, this study uncovers a metabolic vulnerability that may be exploited for treatments of malignancies arising as a direct consequence of SDH loss of function and, possibly, of other TCA cycle defects. Furthermore, the evidence that aspartate levels are markedly depleted in SDHB-deficient cells and tumours raises the possibility that a mild inhibition of aspartate aminotransferases could preferentially limit their proliferative potential as well. Similarly, because PC fixates bicarbonate into pyruvate, inhibition of bicarbonate uptake or synthesis could limit substrate availability for this enzyme, thereby offering a further therapeutic window for the treatment of SDH -mutated tumours.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper
Generation of conditional Sdhb mice and immortalized Sdhb-null mouse kidney cells. A DNA fragment consisting of 240 base pair (bp) homology arms
flanking an F3-KAN-F3-LoxP cassette was recombineered into introns 3-4 of the Sdhb gene of a pool of three bacterial artificial chromosome clones in the EL250 strain of Escherichia coli 30 . Subsequent expression of Flp in these cells enabled excision of the kanamycin-resistance gene. The same cells were then subjected to recombineering with a DNA fragment consisting of 120 bp and 400 bp homology arms flanking an FRT-HYG-FRT-LoxP cassette into introns 2-3. The plasmid pFlexDTA, a modified version of pFlexible 31 , was linearized by NotI-AscI and a retrieval fragment cloned into these sites. This consisted of 1,140 bp of homology sequence bisected by a SwaI site to allow for subsequent linearization. The homology arms of this plasmid are approximately 5 kilobases distal to the Hygro cassette on the bacterial artificial chromosome DNA. The resultant SwaI-linearized vector was used to retrieve DNA sequence from the modified Sdhb locus by recombineering to generate the targeting vector transfected into mid-log phase G4 mouse embryonic stem cells (129S6/SvEvTac × C57BL/6Ncr F1; ref. 32) by electroporation. Electroporation was carried out under standard conditions (250 V; 500 µF; infinite resistance; cuvette width 4 mm) in a Biorad GenePulser XCell with capacitance extender. After plating onto DR4 irradiated mouse embryonic fibroblast monolayers 33 , cells were placed under Hyg selection for 6-7 days. Individual colonies were picked on to 96-well plates for cryopreservation and further analysis. Correct targeting of the vector to the Sdhb locus on both the 5 and 3 sides was confirmed using PCR on genomic DNA prepared from Hyg-resistant colonies. PCR genotyping was done using Expand Long Template (Roche) according to the manufacturer's recommendations. The presence of the isolated LoxP/F3 sequence in introns 3-4 was confirmed separately. Following confirmation of targeting by PCR, clones were recovered and expanded under Hyg-ESC medium before re-confirmation by PCR. Following identification of correctly targeted clones, mouse lines were derived by injection of Sdhb wt/fl ESCs into C57BL/6J blastocysts according to standard protocols 34 . Following breeding of high-percentage male chimaeras, germline offspring were identified by coat colour, and the presence of the modified allele was confirmed by PCR across the isolated LoxP/F3 sequence as described above. Sdhb wt/fl mice were then intercrossed to obtain Sdhb fl/fl mice, which were used to isolate primary epithelial kidney cells following the method described previously 35 qPCR was carried out using a 7500 fast real-time PCR system (Applied Biosystems) and the amplification steps were 95 • C for 20 s, followed by 40 cycles of 95 • C for 3 s and 60 • C for 30 s. The relative quantification of each mRNA was carried out with the comparative threshold cycle method using β-actin for normalization.
Cell number assessment. Cells were plated at 1 × 10 4 cells per well in 24-well plates.
At the specified experimental time, each well was washed once with PBS, trypsinized, re-suspended in a Casyton solution and counted with a Casy cell counter.
Measurement of OCR and ECAR. 2 × 10 4 Sdhb fl/fl cells and 3 × 10 4 Sdhb ∆/∆ cells were plated onto XF96 plates (09814, Seahorse Bioscience) and incubated at 37 • C, 5% CO 2 , for 24 h. The medium was then replaced with 150 µl of unbuffered assay media (Seahorse Bioscience) supplemented with 25 mM glucose, 2% FBS and 1 mM pyruvate (pH 7.4), and cells were then placed at 37 • C in a CO 2 -free incubator for 45 min. OCR and extracellular acidification rate (ECAR) were then recorded using an XF96 extracellular flux analyser (Seahorse Bioscience). OCR and ECAR were normalized to the protein content in each well calculated at the end of the experiments using the Lowry assay. One µM oligomycin A, 0.75 µM CCCP and 1 µM antimycin A were added to measure ATP-coupled, maximal and mitochondrialdependent basal OCR, respectively, as previously reported 36 .
Measurement of SDH activity. The activity of SDH (succinate:coenzyme Q oxidoreductase activity) was measured by a spectrophotometric assay as described previously 37 .
Measurement of the mitochondrial mass. Mitochondrial mass was assessed cytofluorimetrically by measuring the incorporation of 100 nM mitochondrial potential-insensitive dye MitoTracker Green FM (Life Technologies) as described previously 38 .
Mitochondrial isolation and measurement of complex I activity. Mitochondria
were isolated from Sdhb fl/fl and Sdhb ∆/∆ cells as previously described 39 and used to determine levels of several mitochondrial proteins by immunoblotting and to assess the activity of complex I using a dipstick assay kit (Abcam, ab109720), according to the manufacturer's instructions.
Immunoblotting. Cells were washed twice with cold PBS and lysed in radioimmunoprecipitation assay buffer supplemented with protein and phosphatase inhibitor cocktails. Protein concentration was determined with the bicinchoninic acid assay (Thermo Scientific) using BSA as a standard. Equal amounts of protein were mixed with Laemmli buffer ×2 warmed at 95 • C for 5 min, and loaded on 4-12% gels for SDS-PAGE. After electrophoretic separation, proteins were blotted onto 0.22 mm nitrocellulose (Millipore), blocked with 10% non-fat milk in Tris-buffered saline-Tween, and incubated at 4 • C overnight with the following antibodies: anti-SDH b (goat polyclonal Santa Cruz Biotech sc-34150, 1:500), anti-β-tubulin (mouse monoclonal Sigma-Aldrich, T5201, 1:10,000), anti-pyruvate carboxylase (rabbit monoclonal Abcam, ab126707, 1:1,000), anti-NDUFS4 (mouse monoclonal, Abcam, Ab87399, 1:1,000), anti-MTND6 (mouse monoclonal, Invitrogen, A31857, 1:1,000), anti-COX IV (rabbit polyclonal, Abcam, Ab16056, 1:2,000) and anti-membrane integrity WB cocktail (mouse monoclonal, Abcam, Ab110414, 1:1,000). Membranes were then washed and incubated with secondary anti-mouse (926-32212 or 926-32222, LI-COR), anti-rabbit (926-68073, LI-COR) or anti-goat (926-32214, LI-COR) antibodies at 1:10,000 dilution. The infrared scanning was carried out using a Licor Odyssey scanner (channels 700 and 800) and acquired using Image Studio 2.0. DOI: 10.1038/ncb3233 acetonitrile and water (5:3:2), for endo-metabolite determination. Alternatively, an aliquot of the media was diluted in extraction solution for exo-metabolite analyses. Media derived from wells lacking cells but incubated in the same conditions were used as a reference to quantify the exchange rate (consumption/secretion) of exo-metabolites. Both media and cell extracts were centrifuged at 16,000g for 30 min at 4 • C and the supernatants were analysed by LC-MS. For exo-metabolite quantification, aliquots of DMEM media were processed similarly and supplemented with known concentrations of either U-13 C-labelled metabolites or essential and non-essential amino acids to prepare calibration curves. Endo-metabolites were normalized to the protein content in each well calculated, at the end of the experiment, using the Lowry assay. The exchange rates were obtained by normalizing the variation in consumption or secretion of each exo-metabolite to the average protein content of each sample from the beginning of the experiment (t = 0 h) to its end (t = 48 h). For the measurement of fumarate and its isotopologues, a Q-Exactive Orbitrap mass spectrometer (Thermo Scientific) was used together with a Thermo Scientific Dionex Ultimate 3000 high-performance liquid chromatography system. The high-performance liquid chromatography set-up consisted of a ZIC-HILIC column (150 mm × 4.6 mm, 5 µm, SeQuant, Merck KGaA), preceded by a SeQuant ZIC-HILIC guard column (20 mm × 2.1 mm). The aqueous mobile phase solvent is 0.1% formic acid in water and the organic mobile phase is 0.1% formic acid in acetonitrile. The mobile phase gradient runs from 80% organic mobile phase to 50% over the first 12 min, and is then maintained at 50% organic mobile phase for the next 14 min, increased and maintained at 20% organic mobile phase for 8 min, and then equilibrated back to 80% organic mobile phase. The flow rate used is 300 µl min −1 and the column temperature is maintained at 30 • C. Samples are maintained at 4 • C in a chilled autosampler before injection. The total analysis time is 45 min and 5 µl of sample is injected. The Q-Exactive mass spectrometer was operated in full scan mode, with electrospray ionization and polarity switching, over a mass range of 75-1,000m/z at a resolution of 35,000 (at 200m/z). The Q-Exactive was also used in SIM (selected ion monitoring) mode, for improving sensitivity, where only fumarate and its isotopologues were monitored by the mass spectrometer, using negative ion mode and a resolution of 70,000 (at 200m/z). The mass accuracy for both methods was below 5 ppm. Data were acquired with Thermo Xcalibur software. The peak areas of fumarate and its isotopologues were determined using Thermo LCquan software, identified by the exact mass of each singly charged ion and by the known retention time on the high-performance liquid chromatography column. For the unbiased metabolomic analysis and the targeted analysis of all the other metabolites, cell and medium extracts were injected onto a ZIC-pHILIC column (SeQuant, 150 × 2.1 mm, 5 µm). Mobile phase C: 20 mM ammonium carbonate, pH 9.4. Mobile phase D: acetonitrile. The flow rate was 100 µl min −1 over the gradient as follows: 0 min 80% D to 30 min 20% D and the column was then re-equilibrated until 38 min at 80%D. All metabolites were detected over a mass range of 75-1,000m/z using the Exactive Orbitrap mass spectrometer (Thermo Scientific) with electrospray ionization and polarity switching.
Determination of lipogenic AcCoA. Isotopic enrichment in palmitate in cells incubated for 72 h with U-13 C-glucose or U-13 C-glutamine was quantified with LC-MS, and the fraction of labelling of lipogenic AcCoA was inferred from that of palmitate, using the binomial model introduced by Kamphorst and colleagues 40 . The synthesis of palmitate results in the incorporation of eight acetyl groups from AcCoA into palmitate. Each acetyl unit can be unlabelled (M + 0) or fully labelled (M + 2). If p is the M + 2 fraction then the expected M + 2x (x = 1, . . . , 8) fractions (P) of palmitate follow the binomial model equation (1) .
We determined p by fitting the value resulting in the minimum mean squared deviation between the predicted equation (1) and the observed values (fraction at each isotopologues).
Palmitate quantification and GC-MS. For quantification of total intracellular
palmitate level, the cells were cultured in six-well plates. At time of extraction, medium was aspirated, cells rinsed twice with 1 ml room temperature PBS, 0.75 ml of methanol/PBS (1:1, v/v) solution at −20 • C added, and the plates kept at −20 • C for 10 min. Cells were then scraped into a glass tube (Fisher Scientific), chloroform (0.5 ml) and internal standard mixture (20 µl of 50 µg ml −1 triacylglyceride 14:0/17:1/18:1 and PC 17:0/17:0 (Avanti Polar Lipids)) added, the mixture vortexed for 1 min and then centrifuged at 500g for 10 min, and the chloroform layer transferred to a new glass vial. The extract was dried under N 2 , followed by transesterification and formation of fatty acid methyl esters by heating the lipid extract at 100 • C with 80 µl of toluene, 600 µl of methanol and 120 µl of methanolic HCl for 60 min. Thereafter, 400 µl of water was added to the reaction mixture and fatty acid methyl esters were extracted with 300 µl of hexane and analysed by gas chromatography-mass spectrometry (GC-MS). Fatty acid methyl esters were separated on an Agilent 7890B GC system with a Phenomenex ZB-1701 column (30 m × 0.25 mm × 0.25 µm), coupled to an Agilent 7000 triple quadrupole GC-MS system. GC-MS parameters and temperature program were as previously described 41 . Peak integration was carried out with Agilent Mass Hunter B.06.00 software. The peak height of methyl palmitate (C16:0) was normalized to both methyl heptadecanoate (C17:0) and heptadecenoate (C17:1), and the calculated value was used to determine the amount of palmitate (in nanograms) in the sample using a calibration curve.
shRNA interference of mouse Pcx. The lentiviral non-targeted NTC shRNA and shRNA plasmids against Pcx were purchased from Sigma-Aldrich and identified as follows:
Pcx-1 shRNA, TRCN0000112425 (5 -CCGGCCCTTCAGCTATTTGTCCTTT CTCGAGAAAGGACAAATAGCTGAAGGGTTTTTG-3 )
Pcx-4 shRNA, TRCN0000112428 (5 -CCGGGCACTACTTCATCGAGGTCAA CTCGAGTTGACCTCGATGAAGTAGTGCTTTTTG-3 )
Pcx-5 shRNA, TRCN0000112429 (5 -CCGGCTTTCGCTCTAAGGTGCTAAA CTCGAGTTTAGCACCTTAGAGCGAAAGTTTTTG-3 ).
Lentiviral infections were carried out as previously described 18 . Infected cells were incubated with medium containing 4 µg ml −1 puromycin (selection medium) for another 48 h before being used for further experiments.
Immunohistochemistry of human SDHB-associated RCC. Six micrometre cut paraffin-embedded tissue slices of SDHB-associated RCC and non-neoplastic adjacent kidney tissue were immunostained using a Dako Autostainer for PC (Sigma-Aldrich, HPA043922) and Ki-67 (Dako, M7240). Epitope retrieval was carried out at 98 • C in Tris-EDTA retrieval buffer, pH 8. Samples were counterstained with haematoxylin, dehydrated and coverslipped. The diagnostic mutational analysis was carried out by the East of Scotland Regional Genetics service by using NHS standardized mutation screening procedures. PCR amplification was carried out on a Hamilton Starlet. Bidirectional sequencing of all exons was carried out on an ABI Prism 3730 and Mutation Surveyor.
Analyses of human paragangliomas and pheochromocytomas.
Pheochromocytoma/paraganglioma susceptibility genes (SDHA, B, C, D, AF2, RET, VHL, MAX and TMEM127) have been analysed for point mutations and small deletions/insertions in 22 samples available for this study. Bidirectional sequencing of the coding regions and splice sites was carried out on an ABI3130xl genetic analyser and analysed with SeqScape Software. MLPA analysis (VHL p016c2; SDHB, C, D, AF2 p226b2; MAX, SDHA p429b1) and semiquantitative multiplex-PCR (TMEM127) have been carried out to evaluate for a deletion/duplication of one or more exons of these genes and analysed with Coffalyser.net software. RNA was isolated using TRIzol Reagent (Ambion) following the manufacturer's indications and further processed as described above. Tumour metabolites were extracted by incubating 40 mg of tumour tissue in 1 ml of ice-cold extraction solution and further processed as described above.
Tumour xenografts. Sdhb fl/fl and Sdhb ∆/∆ -CL 7 cells were transformed using a pWZL retroviral vector encoding the H-Ras V12 oncogene 33 provided by K. Vousden (Cancer Research UK, Beatson Institute), infected with a non-targeted shRNA (NTC shRNA) or shRNA against Pcx and selected with 4 µg ml −1 puromycin for 7 days. In a first experiment, 2 × 10 6 transformed NTC shRNA and Pcx-5 shRNA cells were subcutaneously injected into the rear flanks of 10 female six-week-old Balb\c Nu nude mice. In a second experiment, 1 × 10 6 transformed NTC shRNA and Pcx-1 shRNA cells were subcutaneously injected into the rear flanks of eight (for Sdhb fl/fl cells) and nine (for Sdhb ∆/∆ cells) male six-week-old Balb\c Nu nude mice. No statistical method was used to predetermine sample size. Tumour lengths (L) and widths (W ) of sagittal sections were measured three times per week using a manual calliper, and tumour volumes were calculated with the formula tumour volume = 0.5 × L × W 2 . Tumour onset was defined by the presence of a tumour mass with a volume of 40 mm 3 or more recorded in at least two consecutive measurements. The fractions of tumour-free mice were determined with GraphPad Prism and their statistical analyses were carried out using the log-rank (Mantel-Cox) test. Where applicable, a statistical permutation test (http://bioinf.wehi.edu.au/software/ compareCurves) was used to compare the statistical significance between curves of the selected genotypes. Ten thousand permutations were used in each analysis. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.
Ethical approval of human and animal studies. The study of human samples included here was approved by the Tayside Tissue Bank Research
